ProMetic Life Sciences Inc.: Oral PBI-1402 Demonstrates Significant Activity in Chemotherapy-Induced Anemia Phase II Clinical Tr

ProMetic Life Sciences Inc. (TSX:PLI)("ProMetic") announces that oral PBI-1402
demonstrates significant activity in patients with chemotherapy-induced anemia
("CIA"), and reduces the need for red blood cell ("RBC") transfusion.


Only 2 patients out of 28 (7%) treated with PBI-1402 required a RBC transfusion,
a response rate greater than 90% with regards to this clinical objective. In the
March 13, 2008 FDA briefing document, the Oncologic Drugs Advisory Committee
emphasizes that the primary objective of treating CIA patients with
erythropoiesis-stimulating agents ("ESAs") as being the ability to reduce the
need for RBC transfusion. The Advisory Committee cites that approximately 50% of
anemic patients receiving chemotherapy required RBC transfusion, and 20%-25% of
patients treated with ESAs still required RBC transfusions.


"These results are very exciting and meet the primary objective that formed the
basis for FDA approval of other ESAs in CIA patients," states Mr. Pierre Laurin,
President and Chief Executive Officer of ProMetic Life Sciences Inc. "This new
encouraging data further supports the potential role PBI-1402 could play in the
management of anemia in patients with cancer," added Mr. Laurin.


CIA patients enrolled in the study received a once daily oral dose of PBI-1402
during a period of eight weeks while undergoing their normal course of
chemotherapy. All patients enrolled have completed the PBI-1402 treatment
period.


About PBI-1402

PBI-1402 is an orally active compound being developed to treat different types
of anemia, such as CIA. PBI-1402 has a distinct mechanism of action and does not
act through EPO receptor. ProMetic has recently expanded its clinical program
for PBI-1402 into the treatment of anemia in patients with myelodysplastic
syndrome ("MDS"), a condition often referred to as "pre-leukemia". In addition,
a new Phase II study in patients with anemia resulting from chronic kidney
disease has been scheduled.


About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. (www.prometic.com) is a biopharmaceutical company
specialized in the research, development, manufacture and marketing of a variety
of commercial applications derived from its proprietary Mimetic Ligand (TM)
enabling technology. This technology is used in large-scale purification of
biologics and the elimination of pathogens. ProMetic is also active in
therapeutic drug development with the mission to bring to market effective,
innovative, lower cost, less toxic products for the treatment of hematology and
cancer. Its drug discovery platform is focused on replacing complex, expensive
proteins with synthetic "drug-like" protein mimetics. Headquartered in Montreal
(Canada), ProMetic has R&D facilities in the U.K., U.S. and Canada,
manufacturing facilities in the U.K. and business development activities in the
U.S., Europe, Asia and the Middle-East.


Forward Looking Statements

This press release contains forward-looking statements about ProMetic's
objectives, strategies and businesses that involve risks and uncertainties.
These statements are "forward-looking" because they are based on our current
expectations about the markets we operate in and on various estimates and
assumptions. Actual events or results may differ materially from those
anticipated in these forward-looking statements if known or unknown risks affect
our business, or if our estimates or assumptions turn out to be inaccurate. Such
risks and assumptions include, but are not limited to, ProMetic's ability to
develop, manufacture, and successfully commercialize value-added pharmaceutical
products, the availability of funds and resources to pursue R&D projects, the
successful and timely completion of clinical studies, the ability of ProMetic to
take advantage of business opportunities in the pharmaceutical industry,
uncertainties related to the regulatory process and general changes in economic
conditions. You will find a more detailed assessment of the risks that could
cause actual events or results to materially differ from our current
expectations on page 21 of ProMetic's Annual Information Form for the year ended
December 31, 2006, under the heading "Risk Factors". As a result, we cannot
guarantee that any forward-looking statement will materialize. We assume no
obligation to update any forward-looking statement even if new information
becomes available, as a result of future events or for any other reason, unless
required by applicable securities laws and regulations.